Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram up to 50 mg in Major Depressive Disorder
NCT00785434Phase 4Completed
- Sponsor
- Community Pharmacology Services
- Start
- Oct 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of escitalopram in major depressive disorder (MDD), sponsored by Community Pharmacology Services. Primary endpoint: Remission (MADRS < 9) at 8 months. Started Oct 2008; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00785434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00785434.